Senores Pharmaceuticals has delivered a sharp surge in earnings for FY26, posting strong growth across revenue, profitability, and key global markets, according to its audited results for the quarter and year ended 31 March 2026.
For Q4 FY26, the company reported a total income of Rs. 190 crore, up 58% year-on-year. EBITDA jumped 144% to Rs. 62 crore, while PAT rose 105% to Rs. 37 crore—signaling a significant margin expansion in the final quarter of the year.
For the full year FY26, momentum remained even stronger. Total income climbed 62% to Rs. 664 crore, EBITDA surged 96% to Rs. 200 crore, and PAT more than doubled, rising 108% to Rs. 122 crore.
Growth was broad-based, but clearly anchored by regulated markets, which expanded 83% in Q4 to Rs. 117.8 crore and 74.6% for FY26 to Rs. 427.4 crore. Emerging markets also grew steadily, while branded generics delivered exceptional percentage growth off a smaller base.
Segment snapshots:
Regulated Markets: Rs. 427.4 crore (+74.6%)
Emerging Markets: Rs. 145.0 crore (+19.7%)
Branded Generics: Rs. 40.0 crore (+385.3%)
Others: Rs. 51.6 crore (+42.7%)
Commenting on the performance, Managing Director Swapnil Shah pointed to strong execution across businesses and a rapidly expanding regulated portfolio.
He said, "We have delivered a robust performance across segments in FY26, driven by operational discipline, consistent execution, and strong momentum in key growth areas despite an uncertain operating environment.
"In the Regulated Markets, our approved ANDA portfolio has more than doubled during the year, increasing from 26 ANDAs as of March 2025 to 51 ANDAs as of March 2026, reflecting the scale and pace of our execution.
"Out of these, 30 approved ANDAs are yet to be commercialized. Additionally, we have 27 more molecules, involving 65+ unique strengths, at different stages of development. This gives us a strong pipeline of products which are expected to be rolled out over the coming years."
He added: "We have expanded our manufacturing footprint and product portfolio through acquisition of Apnar Pharmaceuticals. The acquisition enhances scalability, deepens access to Regulated Markets, enables accelerated product launches, improves operating leverage, margins, and expands CDMO-CMO opportunities, positioning Senores for sustained growth.
"We have commenced product rollouts from the Apnar facility, with initial revenues starting in Q4FY26. While contributions are currently modest, we expect the facility to scale meaningfully and emerge as a key growth driver over the next 12–18 months.
"In Q3FY26, we acquired Zoraya Pharmaceuticals as a step-down subsidiary to strengthen our U.S. marketing and distribution capabilities, enabling direct commercialization of strategic pharmaceutical products in the market.
In April 2026, the MD said, the company entered into a joint venture, Amerisyn, marking a key milestone for our U.S. operations and enabling entry into the high-entry-barrier U.S. government procurement market, including federal, veterans affairs, and military supply programs.
"Our Emerging Markets business is on a steady trajectory as well. With the shift towards niche products, we are now at mid teens EBITDA Margin. Importantly, the Emerging Markets business is now cash flow positive."
